ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report

ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report

SCLC transformation is a phenomenon that is rarely described in ALK-rearranged cancers after treatment with ALK tyrosine kinase inhibitors, and it is exceedingly rare after lorlatinib use. We report the first case of a patient with an ALK-EML4 rearrangement who was resistant to lorlatinib simply due...

Full description

Bibliographic Details
Main Authors:	Huihui Li, BM, Tianqi Song, BM, Xiaoling Xu, MD
Format:	Article
Language:	English
Published:	Elsevier 2023-02-01
Series:	JTO Clinical and Research Reports
Subjects:	Anasplastic lymphoma kinase Lung adenocarcinoma Lorlatinib Resistance Small cell lung cancer Case report
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364323000036

Similar Items

First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
by: Hidetoshi Hayashi, MD, PhD, et al.
Published: (2023-04-01)

Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study
by: Shunsuke Teraoka, MD, et al.
Published: (2024-03-01)

Small intestinal metastasis in a lung adenocarcinoma patient with concurrent EML4-ALK V3 and TP53 mutations after distinct responses to tyrosine kinase inhibitors: A case report
by: Lingling Zhu, et al.
Published: (2024-10-01)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
by: Yuki Takeyasu, MD, et al.
Published: (2022-05-01)

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
by: Marliese Alexander, B.Pharm(Hons), MPH, PhD, et al.
Published: (2023-04-01)

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
by: Jialin Qian, et al.
Published: (2025-03-01)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
by: Yasushi Goto, MD, PhD, et al.
Published: (2023-05-01)

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report
by: Annamaria Catino, et al.
Published: (2022-03-01)

Bilateral optic neuropathy associated with lorlatinib monotherapy for ALK-positive metastatic lung adenocarcinoma
by: Alan W. Kong, et al.
Published: (2024-06-01)

Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report
by: Alexius John, MBBS, FRACP, et al.
Published: (2024-07-01)

Chinese Expert Consensus on Management of Special Adverse Effects  Associated with Lorlatinib
by: Qing ZHOU, et al.
Published: (2022-08-01)

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
by: Qing Zhou, MD, PhD, et al.
Published: (2023-05-01)

Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib
by: Dan Liu, et al.
Published: (2024-03-01)

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib
by: Yuki Sato, et al.
Published: (2024-08-01)

Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report
by: Yutaka Fujiwara, et al.
Published: (2024-08-01)

ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib
by: Jikui Guan, et al.
Published: (2024-01-01)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
by: Zhifeng Ye, et al.
Published: (2023-03-01)

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report
by: Fumihiro Kashizaki, et al.
Published: (2022-08-01)

A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations
by: Ambritha Balasundaram, et al.
Published: (2024-01-01)

Modern treatment of ALK-positive non-small cell lung cancer
by: D. A. Kharagezov, et al.
Published: (2022-06-01)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
by: Rohit Thummalapalli, MD, et al.
Published: (2023-08-01)

Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience
by: K. K. Laktionov, et al.
Published: (2021-12-01)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024-02-01)

Anaplastic Lymphoma Kinase (ALK) Rearrangement of Lung Adenocarcinoma among North Sumatera Population
by: Muhammad Yusuf Adira Putra, et al.
Published: (2025-01-01)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
by: Martin Rupp, et al.
Published: (2023-07-01)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
by: Jackson Ka Chun Leung, M.B.B.S., et al.
Published: (2023-07-01)

Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report
by: Xinyi WANG, et al.
Published: (2024-12-01)

Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report
by: James A. Fletcher, M.B.B.S., et al.
Published: (2024-02-01)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
by: Parvin Begum, PhD, et al.
Published: (2022-09-01)

Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report
by: Ruiqi Niu, et al.
Published: (2024-01-01)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023-11-01)

From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
by: Laura Fabbri, et al.
Published: (2023-12-01)

A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
by: Ting Wang, et al.
Published: (2023-02-01)

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib
by: Shubin W. Shahab, et al.
Published: (2023-02-01)

Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia
by: Lukas Mayer-Suess, et al.
Published: (2024-03-01)

Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations
by: Isabella Wilson, et al.
Published: (2024-08-01)

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
by: Takayuki Kobayashi, MD, et al.
Published: (2023-07-01)

ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
by: Malinda Itchins, BMedSci, M.B.B.S., FRACP, PhD, et al.
Published: (2024-09-01)

Lorlatinib‐induced visual and auditory hallucinations: A case report
by: Jun Hakamata, et al.
Published: (2021-08-01)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
by: Zhe-Rong Zheng, et al.
Published: (2023-03-01)